Bavencio shows clear benefit in urothelial cancer
By Hwang, Byung-woo | translator Kang, Shin-Kook
24.08.22 05:40:39
가나다라
0
1 year into Bavencio’s reimb as first-line maintenance therapy, the rate of patients who switch to Bavencio after chemotherapy increases
RWD confirms effect in the real world...Experts highly rate the benefits of immuno-oncology drugs
Changes in the prescription options for UC remain an issue… academia “Need to consider the advantages and disadvantages of each treatment.”
The treatment landscape for metastatic urothelial cell carcinoma has changed after Bavencio (avelumab) was granted reimbursement as a first-line maintenance therapy in Korea.
Bavencio addressed the high unmet need that had remained for a maintenance therapy option on site, rapidly changing the prescribing pattern.
▲(From the left) Inho Kim, Professor of Oncology at Seoul St. Mary
Merck Biopharma Korea held a press conference celebrating the first anniversary of the reimbursed launch of its Bavencio in Korea, highlighting the changes in Korea’s prescribing environment and Bavencio’s clinical value.The indication for the anti-PD-L1 immuno-oncology drug was expanded in August 2021 to include first-line maintenance therapy for patients wit
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)